InsiderPulse
Dashboard

CORT

Corcept Therapeutics Incorporated

Health CareRussell 2000

Corcept Therapeutics Incorporated insider trading

Corcept Therapeutics Incorporated files with the SEC as a Pharmaceutical Preparations company headquartered in Redwood City, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent CORT insider transactions

7 insiders traded CORT on the open market between Aug 17, 2026 and Sep 16, 2026 — 24 sales worth $32.2M, of which 22 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$32.2M

22 of 24 on a 10b5-1 plan

Net
−$32.2M
Insiders
7

Open-market purchases (code P) and sales (code S) from Corcept Therapeutics Incorporated's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every CORT Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

CORT insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 10 insiders traded CORT on the open market: 2 purchases worth $3.3M and 155 sales worth $125.7M, 143 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 2 purchases ($3.3M) and 81 sales ($62.4M), by 10 insiders.

QuarterBoughtSold
Q2 2026—−$21.7M18 sales · 16 on a plan
Q1 2026+$3.3M2 buys−$3.6M5 sales · all on a plan
Q4 2025—−$21.4M27 sales · 25 on a plan
Q3 2025—−$15.7M31 sales · 30 on a plan
Q2 2025—−$19.2M36 sales · 32 on a plan
Q1 2025—−$40.3M22 sales · all on a plan
Q4 2024—−$2M8 sales · 6 on a plan
Q3 2024—−$1.8M8 sales · 7 on a plan
Largest purchase
+$2.5M of CORT by Baker G Leonard Jr (Director) on Mar 17, 2026.
Largest sale
−$16.2M of CORT by Lyon Joseph Douglas (Chief Accounting & Technology Officer) on Mar 31, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Mahoney David L

    Director

    −$1.7M

    Jun 17, 2026

    20,000 sh · $84.53

  • Wilson James N10b5-1

    Director

    −$486.6K

    Jun 16, 2026

    5,823 sh · $83.57

  • Wilson James N10b5-1

    Director

    −$345.4K

    Jun 16, 2026

    4,177 sh · $82.69

  • Mokari Atabak10b5-1

    Chief Financial Officer

    −$1.6M

    Jun 15, 2026

    19,483 sh · $81.81

  • Mokari Atabak10b5-1

    Chief Financial Officer

    −$896.9K

    Jun 15, 2026

    11,081 sh · $80.94

  • Mokari Atabak10b5-1

    Chief Financial Officer

    −$754.9K

    Jun 15, 2026

    9,434 sh · $80.02

  • Mokari Atabak10b5-1

    Chief Financial Officer

    −$165

    Jun 15, 2026

    2 sh · $82.45

  • Guyer William10b5-1

    Chief Development Officer

    −$1.4M

    Jun 02, 2026

    20,000 sh · $70.60

  • Mokari Atabak10b5-1

    Chief Financial Officer

    −$2.8M

    Jun 01, 2026

    40,000 sh · $70.00

  • Maduck Sean10b5-1

    Officer

    −$1.5M

    Jun 01, 2026

    21,069 sh · $70.11

  • Belanoff Joseph K10b5-1

    Chief Executive Officer · Director

    −$895.3K

    Jun 01, 2026

    12,837 sh · $69.74

  • Maduck Sean10b5-1

    Officer

    −$278.1K

    Jun 01, 2026

    3,931 sh · $70.75

  • Maduck Sean10b5-1

    Officer

    −$3.6M

    May 27, 2026

    54,575 sh · $65.37

  • Maduck Sean10b5-1

    Officer

    −$1.4M

    May 27, 2026

    20,425 sh · $66.16

  • Lyon Joseph Douglas

    Chief Accounting & Technology Officer

    −$325K

    May 27, 2026

    5,000 sh · $65.00

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Corcept Therapeutics Incorporated company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Redwood City, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001088856

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought CORT

What the stock actually did in the 90 days following each open-market purchase

Don't check CORT — let it ping you

Get told the moment an insider moves on CORT

Pro watches Corcept Therapeutics Incorporated for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add CORT to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track CORT on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read CORT insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

HRMYSUPNOMCLHQYDOCSOSCRALHCASTHBDXTECHCAHCNC
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are CORT insiders buying or selling?
Between Aug 17, 2026 and Sep 16, 2026, 7 Corcept Therapeutics Incorporated insiders made no open-market purchases and 24 sales worth $32.2M, a net sale of $32.2M. 22 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much CORT stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 10 Corcept Therapeutics Incorporated insiders made 2 open-market purchases worth $3.3M and 155 sales worth $125.7M. 143 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 2 purchases ($3.3M) and 81 sales ($62.4M). The largest purchase was Baker G Leonard Jr buying $2.5M on Mar 17, 2026. The largest sale was Lyon Joseph Douglas selling $16.2M on Mar 31, 2025.
What was the largest recent CORT insider trade?
Mahoney David L (Director) sold $10.8M of CORT stock on Aug 18, 2026 at about $118.24 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy CORT shares?
No open-market purchase by a Corcept Therapeutics Incorporated insider appears in the filings from Aug 17, 2026 to Sep 16, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Baker G Leonard Jr buying $2.5M on Mar 17, 2026.
Where does CORT insider trading data come from?
From the Form 4 filings Corcept Therapeutics Incorporated's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.